Business
Opus Genetics to Participate in Leading Medical Conferences in May 2026
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. “We look forward to sharing progress across our programs at ARVO and other leading
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cXWyemNkrNdnQ8pvyVh0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MQ--/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.","length":422,"tagName":"p"},{"type":"text","content":"“We look forward to sharing progress across our programs at ARVO and other leading meetings this May, including encouraging findings from our LCA5 and BEST1 gene therapy programs,” said Dr. George Magrath, Chief Executive Officer, Opus Genetics. “At ARVO, we will present previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study, alongside new preclinical and translational work advancing our pipeline. These meetings provide an important opportunity to engage with the ophthalmology community as we work to develop durable, one-time treatments for inherited retinal diseases.”","length":604,"tagName":"p"},{"type":"text","content":"Retinal Therapeutics Innovation Summit 2026","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Title: Safety and Efficacy of OPGx-RHO Silence-and-Replace Gene Therapy for RHO-adRP: Evidence Across Two Large Animal Models","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: May 1, 2026","length":17,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Denver, CO ","length":20,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":175,"olType":false},{"type":"text","content":"Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","length":74,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","...